Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases

被引:2
|
作者
Stanel, Stefan Cristian [1 ,2 ]
Rivera-Ortega, Pilar [1 ]
机构
[1] Univ Manchester, Wythenshawe Hosp, NHS Fdn Trust,North West Lung Ctr, Interstitial Lung Dis ILD Unit, Manchester, England
[2] Univ Manchester, Fac Biol, Med & Hlth, Manchester, England
关键词
progressive fibrosing interstitial lung disease; progressive pulmonary fibrosis; interstitial lung disease; idiopathic pulmonary fibrosis; PF-ILD; PPF; CHRONIC HYPERSENSITIVITY PNEUMONITIS; IDIOPATHIC PULMONARY-FIBROSIS; TELOMERE LENGTH; MULTIDISCIPLINARY;
D O I
10.3389/fmed.2023.1114722
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases
    Katzenstein, Anna-Luise A.
    Mukhopadhyay, Sanjay
    Myers, Jeffrey L.
    HUMAN PATHOLOGY, 2008, 39 (09) : 1275 - 1294
  • [42] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
    Matteson, Eric
    Kelly, Clive
    Distler, Joerg
    Mann-Vold, Anna Maria Hoff
    Seibold, James
    Mittoo, Shikha
    Distler, Oliver
    Goeldner, Rainer-Georg
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [43] Prevalence of progressive fibrosing interstitial lung disease
    Olson, Amy
    Hartmann, Nadine
    Schlenker-Herceg, Rozsa
    Wallace, Laura
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [44] Prevalence of Progressive Fibrosing Interstitial Lung Disease
    Charest-Morin, Xavier
    Olson, Amy
    Wallace, Laura
    Hartmann, Nadine
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 823 - 823
  • [45] Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial
    Koschel, D.
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S.
    Stowasser, S.
    Coeck, C.
    Goeldner, R. G.
    Clerisme-Beaty, E.
    Schlenker-Herceg, R.
    Brown, K. K.
    PNEUMOLOGIE, 2020, 74 : S106 - S107
  • [46] Effects of Nintedanib on Circulating Biomarkers in Subjects with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
    Maher, T. M.
    Jenkins, R. G.
    Bonella, F.
    Assassi, S.
    Diefenbach, C.
    Ittrich, C.
    Rohr, K. B.
    Kolb, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [47] Efficacy and Safety of Nintedanib in Elderly Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
    Moua, T.
    Bonella, F.
    Okamoto, M.
    Tomassetti, S.
    Valenzuela, C.
    Wuyts, W.
    Miede, C.
    Lievens, D.
    Bendstrup, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [48] CHARACTERISTICS OF PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES IN THE ILD-PRO REGISTRY BY TIME BETWEEN DIAGNOSIS AND ENROLLMENT
    Lobo, Leonard
    Liu, Yi
    Li, Peide
    Ramaswamy, Murali
    Swaminathan, Aparna
    Veeraraghavan, Srihari
    Fan, Yanni
    Neely, Megan L.
    Palmer, Scott M.
    Olson, Amy L.
    CHEST, 2023, 164 (04) : 3058A - 3059A
  • [49] Impact of weight loss on outcomes in patients with progressive fibrosing interstitial lung diseases (ILDs)
    Kreuter, M.
    Bendstrup, E.
    Maher, T. M.
    Inoue, Y.
    Miede, C.
    Lievens, D.
    Crestani, B.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [50] Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries
    Hilberg, Ole
    Hoffmann-Vold, Anna-Maria
    Smith, Vanessa
    Bouros, Demosthenes
    Kilpelainen, Maritta
    Guiot, Julien
    Morais, Antonio
    Clemente, Susana
    Daniil, Zoe
    Papakosta, Despina
    Fretheim, Havard
    Neves, Sofia
    Alfaro, Tiago M.
    Antoniou, Katerina M.
    Valveny, Neus
    Asijee, Guus
    Soulard, Stephane
    Wuyts, Wim
    ERJ OPEN RESEARCH, 2022, 8 (01)